Jennifer Swainson

1.3k total citations
30 papers, 638 citations indexed

About

Jennifer Swainson is a scholar working on Pharmacology, Biological Psychiatry and Cellular and Molecular Neuroscience. According to data from OpenAlex, Jennifer Swainson has authored 30 papers receiving a total of 638 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pharmacology, 19 papers in Biological Psychiatry and 6 papers in Cellular and Molecular Neuroscience. Recurrent topics in Jennifer Swainson's work include Treatment of Major Depression (21 papers), Tryptophan and brain disorders (19 papers) and Psychedelics and Drug Studies (5 papers). Jennifer Swainson is often cited by papers focused on Treatment of Major Depression (21 papers), Tryptophan and brain disorders (19 papers) and Psychedelics and Drug Studies (5 papers). Jennifer Swainson collaborates with scholars based in Canada, United States and Netherlands. Jennifer Swainson's co-authors include Atul Khullar, Rejish K. Thomas, Glen B. Baker, Serdar Dursun, Philip G. Tibbo, Dmitriy Matveychuk, Pierre Chue, Larry J. Klassen, Pratap Chokka and Roger S. McIntyre and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neuroscience & Biobehavioral Reviews and Journal of Affective Disorders.

In The Last Decade

Jennifer Swainson

24 papers receiving 630 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jennifer Swainson Canada 12 374 303 137 130 111 30 638
Shakila Meshkat Canada 14 277 0.7× 218 0.7× 113 0.8× 169 1.3× 120 1.1× 70 618
Muhammad Youshay Jawad Canada 14 227 0.6× 172 0.6× 123 0.9× 126 1.0× 89 0.8× 31 551
Atul Khullar Canada 9 319 0.9× 195 0.6× 116 0.8× 89 0.7× 77 0.7× 21 627
Vanina Popova United States 9 586 1.6× 382 1.3× 151 1.1× 63 0.5× 161 1.5× 22 727
Brooke Short Australia 7 351 0.9× 286 0.9× 234 1.7× 82 0.6× 144 1.3× 15 843
Martina Flynn United States 8 436 1.2× 287 0.9× 125 0.9× 55 0.4× 113 1.0× 10 558
Tatjana Dose Germany 7 196 0.5× 177 0.6× 174 1.3× 69 0.5× 83 0.7× 10 658
Sara Costi United States 14 310 0.8× 364 1.2× 76 0.6× 120 0.9× 148 1.3× 28 786
Nicolás A. Núñez United States 14 138 0.4× 115 0.4× 265 1.9× 117 0.9× 94 0.8× 55 711

Countries citing papers authored by Jennifer Swainson

Since Specialization
Citations

This map shows the geographic impact of Jennifer Swainson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Swainson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Swainson more than expected).

Fields of papers citing papers by Jennifer Swainson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Swainson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Swainson. The network helps show where Jennifer Swainson may publish in the future.

Co-authorship network of co-authors of Jennifer Swainson

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Swainson. A scholar is included among the top collaborators of Jennifer Swainson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Swainson. Jennifer Swainson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Meshkat, Shakila, Guoqiang Li, Benjamin T. Dunkley, et al.. (2025). Efficacy and Safety of Glucagon‐Like Peptide‐1 Agonists for Psychiatric Symptoms: A Systematic Review. Brain and Behavior. 15(7). e70661–e70661. 1 indexed citations
2.
3.
Meshkat, Shakila, Richard J. Zeifman, Jennifer Swainson, et al.. (2025). Psychedelics and Suicide-Related Outcomes: A Systematic Review. Journal of Clinical Medicine. 14(5). 1416–1416. 2 indexed citations
4.
Meshkat, Shakila, Yanbo Zhang, Andrew J. Greenshaw, et al.. (2025). Role of ketamine in the treatment of substance use disorders: A systematic review. Journal of Substance Use and Addiction Treatment. 175. 209705–209705. 4 indexed citations
5.
Khullar, Atul, et al.. (2025). Ketamine for mental health - A naturalistic inventory of prescribing practices, safety, and adverse effects. PLOS mental health.. 2(4). e0000215–e0000215.
6.
7.
Swainson, Jennifer. (2025). Ketamine and Perinatal Mental Health: Problems and Potentials. The Canadian Journal of Psychiatry. 70(6). 496–498.
8.
Swainson, Jennifer, et al.. (2025). A framework to assess risks for non-medical use of psychedelics: The liability for abuse of psychedelics questionnaire (LAPQ). SHILAP Revista de lepidopterología. 5(3). 100218–100218. 1 indexed citations
9.
Meshkat, Shakila, Gunjan Malik, Richard J. Zeifman, et al.. (2025). Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review. Neuroscience & Biobehavioral Reviews. 173. 106163–106163.
10.
Swainson, Jennifer, Nisha Ravindran, Raymond W. Lam, et al.. (2024). IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression. Psychiatry Research. 340. 116125–116125. 5 indexed citations
11.
Jawad, Muhammad Youshay, Jennifer Swainson, Joshua D. Di Vincenzo, et al.. (2022). The abuse liability of ketamine: A scoping review of preclinical and clinical studies. Journal of Psychiatric Research. 151. 476–496. 44 indexed citations
12.
Swainson, Jennifer, et al.. (2022). Intravenous ketamine for depression: A clinical discussion reconsidering best practices in acute hypertension management. Frontiers in Psychiatry. 13. 1017504–1017504. 7 indexed citations
13.
14.
15.
Ceban, Felicia, Joshua D. Rosenblat, Kevin Kratiuk, et al.. (2021). Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders. CNS Drugs. 35(9). 925–934. 55 indexed citations
16.
Khullar, Atul, et al.. (2021). The drug liking and craving questionnaire (DLCQ) to evaluate addiction risk for ketamine and esketamine. SHILAP Revista de lepidopterología. 2(1). 100018–100018. 11 indexed citations
17.
Dennett, Liz, et al.. (2021). Impact of Pandemics/Epidemics on Emergency Department Utilization for Mental Health and Substance Use: A Rapid Review. Frontiers in Psychiatry. 12. 615000–615000. 9 indexed citations
18.
Matveychuk, Dmitriy, Rejish K. Thomas, Jennifer Swainson, et al.. (2020). Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. SHILAP Revista de lepidopterología. 10. 3628482225–3628482225. 123 indexed citations
19.
Swainson, Jennifer, M. S. Marsh, & Philip G. Tibbo. (2010). Psychiatric Residents as Teachers: Development and Evaluation of a Teaching Manual. Academic Psychiatry. 34(4). 305–309. 14 indexed citations
20.
Tibbo, Philip G., et al.. (2003). Prevalence and relationship to delusions and hallucinations of anxiety disorders in schizophrenia. Depression and Anxiety. 17(2). 65–72. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shakila Meshkat Breakdown of academic impact, for papers by Muhammad Youshay Jawad Breakdown of academic impact, for papers by Atul Khullar Breakdown of academic impact, for papers by Vanina Popova Breakdown of academic impact, for papers by Brooke Short Breakdown of academic impact, for papers by Martina Flynn Breakdown of academic impact, for papers by Tatjana Dose Breakdown of academic impact, for papers by Sara Costi Breakdown of academic impact, for papers by Nicolás A. Núñez
Rankless by CCL
2026